$14.36
+0.76 (+5.59%)
Open$14.51
Previous Close$13.60
Day High$15.66
Day Low$14.20
52W High$42.12
52W Low$3.66
Volume—
Avg Volume5.6K
Market Cap29.87M
P/E Ratio—
EPS$-18.93
SectorBiotechnology
Analyst Ratings
Strong Buy
7 analysts
Price Target
-13.7% upside
Current
$14.36
$14.36
Target
$12.39
$12.39
$7.78
$12.39 avg
$16.73
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 12.23M | 4.59M | 4.05M |
| Net Income | -15,733,887 | -196,564 | -196,089 |
| Profit Margin | -128.7% | -4.3% | -4.8% |
| EBITDA | -15,282,356 | -265,994 | -241,454 |
| Free Cash Flow | — | -252,687 | -239,821 |
| Rev Growth | — | +16.2% | +0.5% |
| Debt/Equity | 0.20 | 1.06 | 0.93 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $210.39 | -0.18% | 88.1 | 372.39B |
| AMGN | Amgen Inc | $326.31 | -2.95% | 23.0 | 179.23B |
| GILD | Gilead Sciences Inc | $129.58 | -1.88% | 17.4 | 160.50B |
| VRTX | Vertex Pharmaceuticals Inc | $436.95 | -2.99% | 26.4 | 114.32B |
| REGN | Regeneron Pharmaceuticals | $698.25 | -2.05% | 16.7 | 73.89B |
| ALNY | Alnylam Pharmaceuticals Inc | $286.98 | -2.20% | 66.6 | 38.43B |